Supernus Pharmaceuticals IncSupernus Pharmaceuticals Inc - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

Full Sustainability assessment of Supernus Pharmaceuticals Inc are reached by registering for free. This article includes a questions and answers table for Supernus Pharmaceuticals Inc. This Sustainability rating for Supernus Pharmaceuticals Inc represents the company's reporting of the United Nations SDGs.

Supernus Pharmaceuticals Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.6; made up of an environmental score of 6.4, social score of 3.2 and governance score of 6.7.

SDG Transparency Score for Supernus Pharmaceuticals Inc 
Low
0 - 3

5.6

Medium Impact
4 - 6
High
7 - 10
Last Score Update: 2023-07-01
What drives the score for Supernus Pharmaceuticals Inc 
6.4

Environmental

3.2

Social

6.7

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Novartis AG
9.2
High
2Daiichi Sankyo Co Ltd
8.9
High
774Virpax Pharmaceuticals Inc
5.7
High
774Zymeworks Inc
5.7
High
808Supernus Pharmaceuticals Inc
5.6
High
808Armata Pharmaceuticals Inc
5.6
High
808Biostage Inc
5.6
High
.........
2749Xynomic Pharmaceuticals Holdings Inc
0.0
Low
2749Zyden Gentec Ltd
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does Supernus Pharmaceuticals Inc have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does Supernus Pharmaceuticals Inc disclose current and historical energy intensity?

LockedSign up for free to unlock

Does Supernus Pharmaceuticals Inc report the average age of the workforce?

LockedSign up for free to unlock

Does Supernus Pharmaceuticals Inc reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does Supernus Pharmaceuticals Inc disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does Supernus Pharmaceuticals Inc disclose cybersecurity risks?

LockedSign up for free to unlock

Does Supernus Pharmaceuticals Inc offer flexible work?

LockedSign up for free to unlock

Does Supernus Pharmaceuticals Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does Supernus Pharmaceuticals Inc disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does Supernus Pharmaceuticals Inc conduct supply chain audits?

LockedSign up for free to unlock

Does Supernus Pharmaceuticals Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does Supernus Pharmaceuticals Inc conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does Supernus Pharmaceuticals Inc disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does Supernus Pharmaceuticals Inc disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does Supernus Pharmaceuticals Inc disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does Supernus Pharmaceuticals Inc disclose water use targets?

LockedSign up for free to unlock

Does Supernus Pharmaceuticals Inc have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did Supernus Pharmaceuticals Inc have a product recall in the last two years?

LockedSign up for free to unlock

Does Supernus Pharmaceuticals Inc disclose incidents of discrimination?

LockedSign up for free to unlock

Does Supernus Pharmaceuticals Inc allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has Supernus Pharmaceuticals Inc issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does Supernus Pharmaceuticals Inc disclose parental leave metrics?

LockedSign up for free to unlock

Does Supernus Pharmaceuticals Inc disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does Supernus Pharmaceuticals Inc disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does Supernus Pharmaceuticals Inc disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does Supernus Pharmaceuticals Inc support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does Supernus Pharmaceuticals Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does Supernus Pharmaceuticals Inc reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is Supernus Pharmaceuticals Inc involved in embryonic stem cell research?

LockedSign up for free to unlock

Does Supernus Pharmaceuticals Inc disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does Supernus Pharmaceuticals Inc disclose its waste policy?

LockedSign up for free to unlock

Does Supernus Pharmaceuticals Inc report according to TCFD requirements?

LockedSign up for free to unlock

Does Supernus Pharmaceuticals Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does Supernus Pharmaceuticals Inc disclose energy use targets?

LockedSign up for free to unlock

Does Supernus Pharmaceuticals Inc disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does Supernus Pharmaceuticals Inc have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for Supernus Pharmaceuticals Inc
These potential risks are based on the size, segment and geographies of the company.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.

Sorry!

Failed to process!